Sign up

ADAR1 Capital Management, LLC

$2.1B assets · 267 holdings · Q2 2026 · Filed 14 AUG 2026

About ADAR1 Capital Management, LLC’s 13F portfolio

ADAR1 Capital Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , ADAR1 Capital Management, LLC reported $2.1B across 267 US-listed positions (). Its largest position is ABIVAX SA (ABVX) at 11% of the reported book, and its ten biggest holdings make up 42% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$2.1B
Assets (13F)
#1,426
of 8,839 by size
267
Holdings
42%
Top-10 weight
140
Buys
135
Sells
Top holdings · Q2 2026
267 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: ABVX
ABIVAX SA
$80.65
−3.79%
11%
1.8M$240.5M
2
NASDAQ: PTGX
PROTAGONIST THERAPEUTICS INC
$124.02
−2.47%
5.5%
961K$117.8M
3
NASDAQ: ROIV
ROIVANT SCIENCES LTD
$38.96
+0.59%
5.3%
3.2M$111.7M
4
NYSE Arca: SPY
STATE STR SPDR S&P 500 ETF T
$715.87
−1.96%
4.5%
129K$96.4M
5
NASDAQ: IMVT
IMMUNOVANT INC
$32.52
−1.96%
4.2%
2.3M$89.8M
6
NASDAQ: ZLAB
ZAI LAB LTD
$21.92
−0.86%
3.0%
3.4M$64.0M
7
NASDAQ: AGIO
AGIOS PHARMACEUTICALS INC
$28.76
−3.10%
2.2%
1.3M$47.8M
8
NASDAQ: CRNX
CRINETICS PHARMACEUTICALS IN
$84.95
0.00%
2.1%
1.2M$45.7M
9
Cboe BZX: BOXX
EA SERIES TRUST
$119.09
0.00%
1.9%
337K$39.5M
10
NASDAQ: CYTK
CYTOKINETICS INC
$51.46
+0.27%
1.8%
458K$39.0M
11
NASDAQ: SEPN
SEPTERNA INC
$39.20
−0.63%
1.5%
941K$31.5M
12
NASDAQ: AVR
ANTERIS TECHNOLOGIES GLOBAL
$5.09
−2.30%
1.5%
3.1M$31.0M
13
NASDAQ: EDIT
EDITAS MEDICINE INC
$1.71
−3.39%
1.4%
8.9M$28.8M
14
NASDAQ: DNLI
DENALI THERAPEUTICS INC
$18.20
−1.09%
1.2%
1.0M$26.5M
15
NASDAQ: SYRE
SPYRE THERAPEUTICS INC
$97.63
−3.77%
1.2%
284K$25.2M
16
NASDAQ: VIR
VIR BIOTECHNOLOGY INC
$8.87
−3.06%
1.2%
2.5M$25.0M
17
NASDAQ: PRAX
PRAXIS PRECISION MEDICINES I
$310.90
+1.87%
1.2%
74K$24.9M
18
NASDAQ: INSM
INSMED INC
$144.46
+20.58%
1.1%
229K$24.4M
19
NASDAQ: CLDX
CELLDEX THERAPEUTICS INC NEW
$27.96
+1.49%
1.1%
620K$23.1M
20
NASDAQ: VKTX
VIKING THERAPEUTICS INC
$25.84
−1.26%
1.1%
574K$22.4M
21
NASDAQ: TSHA
TAYSHA GENE THERAPIES INC
$3.77
−5.51%
1.0%
3.0M$20.7M
22
NASDAQ: MNPR
MONOPAR THERAPEUTICS INC
$70.29
−0.65%
0.9%
218K$20.1M
23
NASDAQ: OVID
OVID THERAPEUTICS INC
$2.34
+3.54%
0.9%
7.4M$20.0M
24
NASDAQ: ELVN
ENLIVEN THERAPEUTICS INC
$46.41
+3.39%
0.9%
388K$19.7M
25
NASDAQ: ENTA
ENANTA PHARMACEUTICALS INC
$7.98
−3.04%
0.9%
1.3M$19.6M

Showing 1–25 of 267 positions on this page reported in this 13F.

Sector allocation
  • Healthcare89%
  • Financial Services1.1%
  • Real Estate0.0%
  • Communication Services0.0%
  • Industrials0.0%
  • Consumer Cyclical0.0%
  • Technology0.0%
  • Consumer Defensive0.0%
Recent activity · vs 2026-03-31
Bought140
  • AddedABVXABIVAX SA+29.5%$240.5M
  • AddedSPYSTATE STR SPDR S&P 500 ETF T+70.0%$96.4M
  • AddedZLABZAI LAB LTD+136%$64.0M
  • AddedAGIOAGIOS PHARMACEUTICALS INC+816%$47.8M
  • AddedCRNXCRINETICS PHARMACEUTICALS IN+7.3%$45.7M
  • NewEDITEDITAS MEDICINE INC—$28.8M
  • AddedPRAXPRAXIS PRECISION MEDICINES I+4850%$24.9M
  • AddedINSMINSMED INC+546%$24.4M
  • AddedCLDXCELLDEX THERAPEUTICS INC NEW+44.8%$23.1M
  • AddedVKTXVIKING THERAPEUTICS INC+152%$22.4M
Sold135
  • ReducedPTGXPROTAGONIST THERAPEUTICS INC−3.3%$117.8M
  • ReducedROIVROIVANT SCIENCES LTD−3.9%$111.7M
  • ReducedIMVTIMMUNOVANT INC−13.0%$89.8M
  • ReducedCYTKCYTOKINETICS INC−27.6%$39.0M
  • ReducedSEPNSEPTERNA INC−13.7%$31.5M
  • ReducedAVRANTERIS TECHNOLOGIES GLOBAL−17.0%$31.0M
  • ReducedDNLIDENALI THERAPEUTICS INC−45.0%$26.5M
  • ReducedSYRESPYRE THERAPEUTICS INC−16.1%$25.2M
  • ReducedVIRVIR BIOTECHNOLOGY INC−10.5%$25.0M
  • ReducedMNPRMONOPAR THERAPEUTICS INC−17.7%$20.1M
5%+ Beneficial Ownership Stakes · 11 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
TENX
Tenax Therapeutics, Inc.
13G16.4%7.4MFiled 16 NOV 2026
2
RACC
Research Alliance Corporation III
13G9.9%767KFiled 16 NOV 2026
3
AMAN
Amanat Acquisition Corp.
13G9.6%750KFiled 14 AUG 2026
4
JATT
JATT II Acquisition Corp.
13G8.8%683KFiled 16 NOV 2026
5
RNAQ
Rainier Acquisition Corp
13G8.4%743KFiled 16 NOV 2026
6
RACD
Research Alliance Corp IV
13G6.8%525KFiled 16 NOV 2026
7
ADGM
Adagio Medical Holdings, Inc.
13G5.7% · 2 classes1.2MFiled 17 FEB 2026
8
HLXC
Helix Acquisition Corp. III
13G5.6%1.0MFiled 15 MAY 2026
9
TCGX
TCGX Acquisition Corp.
13G5.5%500KFiled 16 NOV 2026
10
PCSC
Perceptive Capital Solutions Corp
13G5.1%457KFiled 17 FEB 2026
11
JTTT
JATT III Acquisition Corp
13G5.1%454KFiled 16 NOV 2026

Showing all 11 disclosed stakes.

Reading ADAR1 Capital Management, LLC’s 13F portfolio

ADAR1 Capital Management, LLC’s $2.1B 13F book is spread across 267 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 42%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are ABVX, PTGX, ROIV, SPY and IMVT, led by ABIVAX SA (ABVX) at 11% of the portfolio. The heaviest sector exposure is Healthcare (89%), then Financial Services (1%).

What ADAR1 Capital Management, LLC changed last quarter

Between 2026-03-31 and Q2 2026, ADAR1 Capital Management, LLC was roughly balanced between buying and selling: it opened 44 new positions and added to 96 more, while trimming 64 and closing 71 outright. Against a 267-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ABIVAX SA (ABVX), and its biggest reduction was PROTAGONIST THERAPEUTICS INC (PTGX).

What a 13F does and doesn’t reveal

A 13F captures only ADAR1 Capital Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names ADAR1 Capital Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. ADAR1 Capital Management, LLC's profile on this page is built directly from those filings.

How current is the 13F data on ADAR1 Capital Management, LLC's page?

It reflects ADAR1 Capital Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When ADAR1 Capital Management, LLC files its next quarterly report, this page refreshes automatically.

Can I see ADAR1 Capital Management, LLC's complete list of holdings?

This page highlights ADAR1 Capital Management, LLC's largest positions rather than all 267 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under ADAR1 Capital Management, LLC's filings.

Does a 13F show everything ADAR1 Capital Management, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of ADAR1 Capital Management, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why ADAR1 Capital Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.